A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01871311 |
Recruitment Status :
Terminated
(Primary investigator left the institution.)
First Posted : June 6, 2013
Last Update Posted : February 8, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer Head and Neck Cancer | Drug: Nilotinib + Cetuximab | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab |
Study Start Date : | May 2014 |
Actual Primary Completion Date : | December 2016 |
Actual Study Completion Date : | December 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Nilotinib + Cetuximab
All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
|
Drug: Nilotinib + Cetuximab
Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly Three dose levels for nilotinib: Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity. |
- Maximum tolerated dose [ Time Frame: 18 months ]The dose at which </= 1 out of 6 subjects experiences a dose limiting toxicity

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck
-
Previous therapy:
- Patients must have progressed after standard therapy for metastatic/recurrent disease, including irinotecan and oxaliplatin-containing regimens for patients with CRC and platinum-containing regimens for patients with H&NSCC.
- Patients may have received cetuximab or panitumumab previously
- Ability to swallow medication tablets by mouth (which may include taking nilotinib mixed in apple sauce)
- At least one measurable lesion by RECIST criteria
- A tumor lesion that can be readily biopsied using a core needle via clinical exam or image-guidance.
- Over the age of 18 years and able to provide informed consent
-
Adequate kidney, liver, and bone marrow function as follows:
- Hemoglobin >/= 8.0 gm/dL
- Absolute neutrophil count >/= 1500
- Platelet count >/= 100,000
- Creatinine within institutional normal limits or glomerular filtration rate > 60
- Total bilirubin f. AST and ALT
- Life expectancy of greater than 3 months
- ECOG performance status
- Normal left ventricular ejection fraction, defined as EF > 50%
Exclusion Criteria:
- Chemotherapy or surgery within 4 weeks prior to treatment start
- Radiation treatment within 3 weeks prior to treatment start
- Prior therapy with nilotinib, ponatinib, dasatinib, or imatinib
- Untreated brain metastases or neurologically unstable central nervous system metastases; CNS metastases will be considered stable if there is no new nor enlarging lesions for one month, and the patient remains off steroids and anti-epileptics for the same time period
- Any severe or uncontrolled medical condition or other condition that could affect participation in this study, including: unstable angina, uncontrolled hypertension, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction
- Diarrhea > Grade 1 at baseline
- Concomitant medication or herbal therapy known to inhibit CYP3A4
- Gastrointestinal tract disease resulting in the inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease
- Ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade >/= 2
- Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation >/= 3 beats in a row)
- Serious cardiac arrhythmia requiring medication
- QTc interval > 500 msec
- Female patients who are pregnant or breast feeding, or adults who are of reproductive potential and are unwilling to refrain from conceiving a child during study treatment
- Patients unwilling or unable to comply with the protocol, or provide informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01871311
United States, District of Columbia | |
Georgetown Lombardi Comprehensive Cancer Center | |
Washington, District of Columbia, United States, 20007 |
Principal Investigator: | Ann W Gramza, MD | Georgetown University |
Responsible Party: | Georgetown University |
ClinicalTrials.gov Identifier: | NCT01871311 |
Other Study ID Numbers: |
2013-0039 |
First Posted: | June 6, 2013 Key Record Dates |
Last Update Posted: | February 8, 2019 |
Last Verified: | February 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
metastatic Kras wildtype squamous cell carcinoma cetuximab nilotinib |
Head and Neck Neoplasms Neoplasms by Site Neoplasms |
Cetuximab Antineoplastic Agents, Immunological Antineoplastic Agents |